Details of the Drug Reposition

General Information of This Drug (ID: DMODLN7)

Drug Name
IRX-2   DMODLN7

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 2 [1]
Squamous cell carcinoma DISQVIFL 2B60-2D01 Phase 2 [2]
Head and neck cancer DISBPSQZ 2D42 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Phase 1 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
leukaemia DISS7D1V 2A60-2B33 Investigative [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.